The CIIC grouping depends on a set of core partners that support our staff and research, and our projects benefits from a broad range of outstanding local facilities. In addition, much of our research is supported by external grants from a range of funding bodies, and and commerical and translational aspects benefit from a number of key industrial collaborations. Expand the tabs below to explore our core partners, funding bodies, key facilities, and some of our industrial connections.
- Core Partners
Founded in 1900, Birmingham grew out of the radical vision of its first Chancellor, Joseph Chamberlain, and was England’s first civic university where students from all religions and backgrounds were accepted on an equal basis. From the embryonic beginnings of our Medical School in 1825, Birmingham has maintained the spirit of innovation of our founder and was awarded "University of the Year" for 2013.
Queen Elizabeth Hospital Birmingham (QEHB), which is run by University Hospitals Birmingham NHS Foundation Trust (UHB), is recognised as one of the leading hospitals in Europe and has an international reputation for quality of care, informatics/IT, clinical training and research.
Queen Elizabeth Hospital Birmingham Charity exists to support the patients of University Hospitals Birmingham NHS Foundation Trust by providing extra equipment and facilities at the Queen Elizabeth and Selly Oak hospitals, and by funding research, all of which are over and above core NHS services.
Located in Birmingham City Centre on Steelhouse Lane, Birmingham Children's Hospital provides the widest range of children’s health services for young patients from Birmingham, the West Midlands and beyond, with over 240,000 patient visits every year.
Birmingham Health Partners is a strategic alliance between University Hospitals Birmingham NHS Foundation Trust, University of Birmingham and Birmingham Children’s Hospital NHS Foundation Trust bringing together clinical, scientific and academic excellence across an integrated medical and life sciences campus
- Funding bodies
CRUK is the world's largest independent cancer research charity. It funds research across the UK into the prevention, diagnosis and treatment of the disease. It also provides information about cancer and runs campaigns aimed at raising awareness of the disease and influencing public policy.
Leukaemia & Lymphoma Research is a leading charity dedicated to the improving the lives of patients in Great Britain with all types of blood cancer, including leukaemia, lymphoma and myeloma. In 2012/2013 it invested more than £32 million into research to beat blood cancer.
The Medical Research Council (MRC) is a publicly funded government agency responsible for co-ordinating and funding medical research in the United Kingdom. The MRC focuses on funding high-impact medically relevant research, and this has resulted in a number of medical breakthroughs, including the development of penicillin and the discovery of the structure of DNA. Research funded by the MRC has also produced 30 Nobel Prize winners to date.
The National Institute for Health Research (NIHR) is a large, multi-faceted and nationally distributed organisation, funded through the Department of Health to improve the health and wealth of the nation through research. The NIHR funds applied health research programmes address a broad range of health priorities, aiming to drive faster translation of basic science discoveries into tangible benefits for patients and the economy.
The Wellcome Trust aims to achieve extraordinary improvements in human and animal health,by supporting outstanding biomedical research, research in the medical humanities, public engagement, and social and ethical aspects of health and biomedical science.
The Kay Kendall Leukaemia Fund supports research on aspects of leukaemia and for relevant studies on related haematological malignancies. Research on approaches likely to improve treatment and care of leukaemia patients, and prevention of leukaemia or related diseases, is prioritized, as well as related capital and equipment requirements.
The Cancer Research UK Clinical Trials Unit (CRCTU) is one of the largest cancer trials units in the UK and has been in existence for more than 30 years. Based in the School of Cancer Sciences at the University of Birmingham, it was one of the first NCRI accredited units and is a UKCRN registered trials unit.
The NIHR/Wellcome Trust Clinical Rearch Facility (CRF) is a joint initiative involving UoB, UHB, and Birmingham Children's Hospital NHS Trust. It provides state-of-the-art facilities for experimental medicine and is the main platform for early phase, cutting edge translational research in Birmingham.
The Clinical Immunology Service is a CPA-accredited facility that has developed into one of the largest diagnostic immunology services in the country. It provides a comprehensive laboratory diagnostic service that includes immunophenotyping in haematolymphoid malignancy and immunodeficiency, autoimmune serology, immunochemistry, allergy, cellular and neuroimmunology testing.
The University of Birmingham Human Biomateirals Resource Centre (HBRC) is a Human Tissue Authority (HTA)-licensed human tissue biorepository, dedicated to human tissue collection, storage, and distribution to researchers. It provides bespoke tissue collection, processing and histopathology services, access to diverse tissue samples and disease settings, and annotation of samples with appropriate demographic/clinical data, in an ethically approved setting whereby investigators do not generally require project-specific approval.
Birmingham ECMC aims to improve the feasibility and quality of research in the areas of immunotherapy and gene therapy, translational genetics and biomarkers. This is being conducted in many different types of cancer. The Centre has established bio-repositories, developed antibody-based assays and conducted various immunotherapy/gene therapy trials.
The Centre for Clinical Haematology is an integrated translational clinical centre that delivers early and late phase clinical trials in haemato-oncology and stem cell transplantation to a catchment region in excess of 5 million. Its co-location with the largest adult stem cell transplant programme in the UK has facilitated the development of an internationally competitive portfolio of early phase clinical trials in haematopoietic transplantation and immunotherapy.
NHS Blood and Transplant is a Special Health Authority, dedicated to saving and improving lives through a wide range of transplant-related services provided to the NHS. Core activities include optimizing the supply of blood, organs, stem cells and tissues to patients, and research and development into new approaches with the aim of improving patient outcomes.
The Centre for Liver Research (CLR) is a University of Birmingham-based research grouping focussed on the scientific and translational aspects of human liver disease. Since 2008, the CLR has been a National Institute for Health Research (NIHR) Biomedical Research Unit (NIHR Birmingham Liver BRU), with joint funding to UHB NHS Foundation Trust in partnership with the University of Birmingham, and funding renewed in 2011 for a further 5 years (2012-17) to continue a translational research programme in liver disease.
The Birmingham Clinical Trials Unit (BCTU) is a second major clinical trials unit based at the University of Birmingham, which provides complementary strengths to the CRCTU unit and receives NIHR Clinical Trials Unit support funding. The BCTU provides scientific, technical and computing expertise needed to support clinical trial research from conception through to completion, and has a diverse range of trials in its portfolio, including strengths in phase III trials, development of diagnostic tests, trials methodology, and clinical trials training.
The Institute of Translational Medicine is a £24 million initiative that will serve as the engine to translate the very latest scientific research findings from the University into enhanced treatments for patients across a range of major diseases including cancer and liver disease. The ITM will build on Birmingham’s excellent track record in clinical trials, co-locating patients alongside clinicians and researchers. It will also promote enhanced collaborative links between SME/large pharma/ biotechnology firms and clinicians and academics, bringing additional investment into the city.
Alta Innovations Ltd, is the University of Birmingham's technology transfer company, which provides expert technology transfer services to University researchers and external businesses. Through a dedicated spinout venture development and business intelligence team, Alta proactively aims to establish new spinout companies to exploit the findings of the Univerity’s research, with the aim of establishing sustainable ventures prioritizing significant financial growth and successful technology application.
Cancer Research Technology (CRT) develops and commercialises new discoveries in cancer research, capitalizing on the research and connections of its parent organization, Cancer Research UK. CRT aims to translate promising research into commercial propositions for the greatest patient benefit and maximum financial return, and has developed strong links with leading clinical and academic institutions, pharmaceutical companies, and biotech companies worldwide.
Miltenyi Biotec is committed to the advancement of biomedical research and cellular therapy, and comprises a vibrant team of more than 1200 biomedical scientists, physicians, engineers, and support groups. The company develops and manufactures a portfolio of outstanding products ranging from unique cell labeling reagents, through sophisticated cell separation and analysis devices, to innovative systems for clinical applications.
Bioscience Ventures (BSVL) is a centre of excellence for the commercialisation of medical diagnostics and services, developed by combining world class intellectual property with industry and commercial expertise. The company operates from the campus of The University of Birmingham in the UK. The primary objective is to enhance and maximise the value of intellectual property in the field of in vitro diagnostics. BSVL is developing new diagnostic tools and platform technologies to meet clinical needs in fields such as cancer and genetic-related diseases.
Serascience Limited is a specialist cancer diagnostic company established in April 2011 to develop medical devices for the diagnosis and management of patients with myeloma and related disorders, collectively known as B-cell dyscrasias. It aims to improve patient management through better diagnostic and prognostic assessment. Serascience also supplies a broad range of class and subclass specific anti immunoglobulin antibodies, for research use.
Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology (patents filed) enabling GMP compliant manufacture of antigen-specific T cells and employs a team of production specialists led by Rainer Knaus, PhD and Katy Newton, PhD. The in-house trial management team, led by Karen Hodgkin, has unique expertise in planning and executing cell therapy trials.
The Cell Therapy Catapult was established in 2012 as a centre of excellence in innovation, with the core purpose of building a world-leading cell therapy industry in the UK. Supported by the Technology Strategy Board, its mission is to drive the growth of the industry by helping cell therapy organisations across the world translate early stage research into commercially viable and investable therapies.